← Leaderboards
Antonio Jimeno
University Of Colorado Denver
$15,496,689
Attributed
$17,430,247
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,503,332 · 12
By mechanism
P50$13,310,508 · 4
R01$11,448,320 · 4
T32$1,480,205 · 1
R21$1,019,584 · 2
R56$244,715 · 1
Top collaborators
- Xiao-Jing Wang14 shared
- Eduardo Davila6 shared
- Mary Elaine Reyland1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Stephen B. Keysar$311,000
- Eduardo Davila$8,435,659
- Mary Elaine Reyland$13,618,689
- Kelsey J Weigel$36,789
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorIn VivoCellsSignal TransductionHead And Neck CancerMalignant NeoplasmsResistanceClinical TrialsPharmaceutical PreparationsCancer CellGrowthPathway InteractionsTranslatingAffectImmuneHead And Neck StructureProteinsColoradoImmunotherapyTranslationsBaseOncogenicMediatingImplant
Grant awards (56)
Colorado Head and Neck Cancer SPORE$1,950,049
P50 · FY2025 · CA · contact PI
Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer$528,427
R01 · FY2025 · CA · contact PI
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112$497,893
R01 · FY2025 · DE · contact PI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer$369,943
P50 · FY2025 · CA · contact PI
Colorado HNC SPORE Administrative Core$313,183
P50 · FY2025 · CA · contact PI
Cell Immunotherapy and Experimental Therapeutics Program (CIETP).$227,238
T32 · FY2025 · CA · contact PI
Colorado Head and Neck Cancer SPORE$89,760
P50 · FY2025 · CA · contact PI
Colorado Head and Neck Cancer SPORE$1,813,896
P50 · FY2024 · CA · contact PI
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112$487,936
R01 · FY2024 · DE · contact PI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer$326,081
P50 · FY2024 · CA · contact PI
Colorado HNC SPORE Administrative Core$294,852
P50 · FY2024 · CA · contact PI
Colorado Head and Neck Cancer SPORE$89,990
P50 · FY2024 · CA · contact PI
Colorado Head and Neck Cancer SPORE$46,330
P50 · FY2024 · CA · contact PI
Colorado Head and Neck Cancer SPORE$1,817,388
P50 · FY2023 · CA · contact PI
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112$497,893
R01 · FY2023 · DE · contact PI
Colorado Head and Neck Cancer SPORE$475,000
P50 · FY2023 · CA · contact PI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer$328,151
P50 · FY2023 · CA · contact PI
Colorado HNC SPORE Administrative Core$296,018
P50 · FY2023 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$130,419
T32 · FY2023 · CA · contact PI
Colorado Head and Neck Cancer SPORE$1,822,219
P50 · FY2022 · CA · contact PI
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112$492,914
R01 · FY2022 · DE · contact PI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer$328,151
P50 · FY2022 · CA · contact PI
Colorado HNC SPORE Administrative Core$296,019
P50 · FY2022 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$286,113
T32 · FY2022 · CA · contact PI
Colorado Head and Neck Cancer SPORE$1,968,453
P50 · FY2021 · CA · contact PI
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112$497,893
R01 · FY2021 · DE · contact PI
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$467,285
R01 · FY2021 · CA · contact PI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer$366,727
P50 · FY2021 · CA · contact PI
Colorado HNC SPORE Administrative Core$318,298
P50 · FY2021 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$315,418
T32 · FY2021 · CA · contact PI
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$538,860
R01 · FY2020 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$345,257
T32 · FY2020 · CA · contact PI
Development of an autologous humanized model of melanoma exploring human thymic education capacity$580,793
R01 · FY2019 · CA · contact PI
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$453,267
R01 · FY2019 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$175,760
T32 · FY2019 · CA · contact PI
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$69,427
R01 · FY2019 · CA · contact PI
Development of an autologous humanized model of melanoma exploring human thymic education capacity$580,793
R01 · FY2018 · CA · contact PI
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$467,285
R01 · FY2018 · CA · contact PI
SOX-driven regulation of Programmed-Death Ligands in HNSCC. Predoc Fellow: Cera Nieto$71,575
R01 · FY2018 · CA · contact PI
Development of an autologous humanized model of melanoma exploring human thymic education capacity$580,793
R01 · FY2017 · CA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$570,269
R01 · FY2017 · DE
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability$467,285
R01 · FY2017 · CA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$501,568
R01 · FY2016 · DE
Identifying oral cancer stem cell properties affected by the microenvironment$68,701
R01 · FY2016 · DE
Identifying oral cancer stem cell properties affected by the microenvironment$501,568
R01 · FY2015 · DE
Identifying oral cancer stem cell properties affected by the microenvironment$500,090
R01 · FY2014 · DE
Hedgehog signaling in head and neck cancer stem cells, and its role in resistance$390,851
R01 · FY2014 · CA · contact PI
Hedgehog signaling in head and neck cancer stem cells, and its role in resistance$372,704
R01 · FY2013 · CA · contact PI
Hedgehog signaling in head and neck cancer stem cells, and its role in resistance$414,711
R01 · FY2012 · CA · contact PI
Rational combination of EGFR and Hedgehog inhibitors in head and neck cancer$317,475
R21 · FY2012 · CA · contact PI
Functional characterization of salivary gland cancers and development of patient$244,715
R56 · FY2012 · DE
Hedgehog signaling in head and neck cancer stem cells, and its role in resistance$413,606
R01 · FY2011 · CA · contact PI
Rational combination of EGFR and Hedgehog inhibitors in head and neck cancer$317,475
R21 · FY2011 · CA · contact PI
Hedgehog signaling in head and neck cancer stem cells, and its role in resistance$433,933
R01 · FY2010 · CA · contact PI
Rational generation of a head and neck squamous cell cancer direct xenograft mode$206,217
R21 · FY2010 · DE · contact PI
Rational generation of a head and neck squamous cell cancer direct xenograft mode$178,417
R21 · FY2009 · DE · contact PI